ISMRM22 - Standardization & Integration in Body MRI

Joint Annual Meeting ISMRM-ESMRMB & ISMRT 31st Annual Meeting • 07-12 May 2022 • London, UK

Standardization & Integration in Body MRI

Onsite Tutorial

ORGANIZERS: Masako Kataoka, Jurgen Fütterer, Jeffrey Maki, Katja Pinker-Domenig, Hero Hussain

Saturday, 07 May 2022

S11 (Breakout B)

13:00 - 17:00

Moderators:
Integrated Imaging of the Body (PET/MR) & Whole-Body MRI I: Nandita DeSouza
Integrated Imaging of the Body (PET/MR) & Whole-Body MRI II: Alan McMillan
Protocols & Reporting for Staging MRI II: Evis Sala
Protocols & Reporting for Staging MRI I: Francesco Giganti

Skill Level: Basic to Intermediate

Session Number: ET-03

Session Number: ET-03

Overview
This course aims to cover clinically relevant MRI topics in an interactive way. The first half covers -RADS format standardization and decision tree. The use of MRI in multi-institutional studies or clinical trials is increasing by these standardized lexicon and scoring/evaluation systems. Another new topic is integrated imaging: PET/MR. This combination allows us to obtain more information in oncology.

Target Audience
Mainly clinicians; researchers in this field are also welcome.

Educational Objectives
As a result of attending this course, participants should be able to:
- Classify or score target disease in a standardized way;
- Describe the benefit of integrated PET/MR over MR alone; and
- Explain the application of -RADS format.

	Integrated Imaging of the Body (PET/MR) & Whole-Body MRI I
13:00		PET/MRI: Technical Considerations View the Presentation Alan McMillan PET/MR integrates two modalities that are highly complementary. This presentation discusses some of the technical considerations relating to integration of PET and MRI, attenuation correction, and optimization of imaging protocols.
13:25		PET/MRI: A Clinical Primer View the Presentation Clemens Cyran
	Integrated Imaging of the Body (PET/MR) & Whole-Body MRI II
13:50		Use Cases: PET/MRI in Hematologic Malignancies & Neuroendocrine Tumors View the Presentation Marius Mayerhoefer
14:15		Use Cases: PET/MRI in Prostate Cancer Video Unavailable Spencer Behr
14:40		Break & Meet the Teachers
	Protocols & Reporting for Staging MRI I
15:05		Bladder Cancer: VI-RADS View the Presentation Valeria Panebianco The purpose of the talk is to describe the VI-RADS scoring system aimed at standardization of MRI acquisition, interpretation, and reporting for urinary bladder cancer (BCa). An insight will be given on the BCa diagnostic issues, MRI applications for BCa local staging with assessment of muscle invasiveness, and clinical implications of the score for the disease management. In addition, future prospective of the score applicability will be provided, on its role in patients’ stratification for therapeutic planning, disease surveillance, and for the evaluation of response to therapy. Finally, a clinical series with multiple-choice questions will be shown.
15:30		Prostate MRI: PI-RADS View the Presentation Baris Turkbey
	Protocols & Reporting for Staging MRI II
15:55		Whole-Body MRI: MET-RADS-P Video Unavailable Anwar Padhani Learning Objectives: •To provide a rationale for the use of WB-MRI when evaluating malignant metastatic disease extent and for therapy response assessments •To show how measurements are acquired distinguishing between tumor detection (core) and response assessment (comprehensive) protocols that are MET-RADS compliant •To highlight and review the MET-RADS response assessment criteria and their application •To illustrate MET-RADS usage with case examples and to provide data on MET-RADS use in clinical practise •Outline the next steps for MET-RADS development
16:20		Rectal Cancer Staging View the Presentation Hina Arif-Tiwari MR imaging for rectal cancer plays a key role in driving management decisions by assisting the multidisciplinary team colorectal cancer team. The decision for surgery +/- neoadjuvant chemotherapy is based on tumor staging on MRI. Good quality rectal cancer MRI protocol and standardized reporting enables the radiologist (a) To provide rectal cancer staging with T and N categories (b) To describe cancer location thereby directing surgical method of choice (c) detect the presence of extramural vascular invasion (EMVI) (d) delineate tumor extension in the mesorectal fascia and (e) identify tumor infiltration into anal sphincter complex in low rectal cancers.